SE9303612D0 - New use - Google Patents

New use

Info

Publication number
SE9303612D0
SE9303612D0 SE9303612A SE9303612A SE9303612D0 SE 9303612 D0 SE9303612 D0 SE 9303612D0 SE 9303612 A SE9303612 A SE 9303612A SE 9303612 A SE9303612 A SE 9303612A SE 9303612 D0 SE9303612 D0 SE 9303612D0
Authority
SE
Sweden
Prior art keywords
medicament
pla2
heparin
phospholipases
low
Prior art date
Application number
SE9303612A
Other languages
Swedish (sv)
Inventor
Lars Aa Hanson
Andrej Tarkowski
Bruno Lomonte
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9303612A priority Critical patent/SE9303612D0/en
Publication of SE9303612D0 publication Critical patent/SE9303612D0/en
Priority to AU81195/94A priority patent/AU8119594A/en
Priority to PCT/SE1994/001030 priority patent/WO1995012403A1/en

Links

Abstract

The present invention relates to the use of low anticoagulant heparin (LA-heparin), low molecular weight-low anticoagulant heparin (LMW-LA-Heparin) or low anticoagulant heparan sulphate for the manufacture of a medicament regulating phospholipases A2 (PLA2). The medicament can be used against myotoxic phospholipases A2 (PLA2) and against bites from snakes or insects. The medicament also inhibits cellular PLA2 in human leukocytes and can be used for treating tissue damages caused by PLA2 and function as an anti-inflammatory medicament. The medicament can be adapted for injectable, topical or oral administration.
SE9303612A 1993-11-02 1993-11-02 New use SE9303612D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9303612A SE9303612D0 (en) 1993-11-02 1993-11-02 New use
AU81195/94A AU8119594A (en) 1993-11-02 1994-11-02 Use of low anticoagulant heparinderivatives
PCT/SE1994/001030 WO1995012403A1 (en) 1993-11-02 1994-11-02 Use of low anticoagulant heparinderivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9303612A SE9303612D0 (en) 1993-11-02 1993-11-02 New use

Publications (1)

Publication Number Publication Date
SE9303612D0 true SE9303612D0 (en) 1993-11-02

Family

ID=20391615

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9303612A SE9303612D0 (en) 1993-11-02 1993-11-02 New use

Country Status (3)

Country Link
AU (1) AU8119594A (en)
SE (1) SE9303612D0 (en)
WO (1) WO1995012403A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
BR112020019213A2 (en) 2018-03-27 2021-01-05 Brian Lohse MYOTOXIN NEUTRALIZING PEPTIDES, COMPOSITION THAT UNDERSTANDS THE SAID PEPTIDE AND USE OF THE SAME TO TREAT POISONING

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases

Also Published As

Publication number Publication date
WO1995012403A1 (en) 1995-05-11
AU8119594A (en) 1995-05-23

Similar Documents

Publication Publication Date Title
DE69920757D1 (en) IMMUNE SUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES
DE69108048T2 (en) DERIVATIVES OF HYDROXAMIC ACID AND N-HYDROXY URINE, AND THEIR USE.
DE69526120T2 (en) USE OF NEBIVOLOL AS AN ANTI-ATHEROGENIC AGENT
UA49869C2 (en) NAPHTHYL-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHOD FOR TREATMENT (VARIANTS), METHOD FOR INHIBITING HUMAN FACTOR Xa OR IIa
DE69710065D1 (en) Androstene DERIVATIVES
ATE282425T1 (en) METHOD FOR TREATING ENDOTHELIAL INJURIES
DE69731610D1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
EA200500804A1 (en) Topical Anti-infective Compositions
SE9602931L (en) New medical use
ATE245452T1 (en) HYALURONATE LYASE AS A PENETRATION PROMOTER IN TOPICAL AGENTS
ATE336997T1 (en) FULVIC ACID AND ITS USE IN THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
EA199900542A1 (en) COMPOUNDS OF SULPHONIC ACID OR SULPHONYLAMINO-N- (HETEROARALKYL) -ASAGHETHROCYCLOSYME
DK1167354T3 (en) Racemic hypersensitivity A
PT888327E (en) BENZOPIRANE DERIVATIVES THAT MAY HAVE AN ANTAGONISTIC ACTION OF LEUKOTRIENES
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
BRPI0414887A (en) methods of treatment, prevention, delay of onset or reduction of effects of proinflammatory cytokines on a mammal and treatment, prevention, delay of onset of a condition associated with an effect of proinflammatory cytokines on a mammal, and, pharmaceutical composition
SE9303612D0 (en) New use
DE69705110D1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN
ATE126061T1 (en) USE OF LITHIUM FOR THE TREATMENT OR PROPHYLAXIS OF MOLLUSCUM CONTAGIUSUM.
BR9809673A (en) Triptolide derivatives useful in the treatment of autoimmune diseases
NO20003510D0 (en) Fat-Binding Polymers
NO990450L (en) Treatment of mental disorders
DE69103773D1 (en) DERIVATIVES OF HYDROXAMIC ACID INHIBIT THE LIPOXYGENASE.
ATE222768T1 (en) CTLA-8 IN COMBINATION WITH G-CSF OR WITH G-CSF AND IL-6, AND USE OF CTLA-8 TO TREAT INFECTIONS
PT1058544E (en) INHIBITION OF TNF ACTIVITY